34 related articles for article (PubMed ID: 10702885)
1. Pharmacokinetics and Tolerability of a Single Dose of Apraglutide, a Novel, Long-Acting, Synthetic glucagon-like peptide-2 Analog With a Unique Pharmacologic Profile, in Individuals With Impaired Renal Function.
Greig G; Youssef NN; Bolognani F
J Clin Pharmacol; 2024 Jun; 64(6):744-754. PubMed ID: 38465515
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and Safety of the Novel Selective Progesterone Receptor Modulator Vilaprisan in Participants With Renal Impairment.
Schultze-Mosgau MH; Lasseter KC; Marbury T; Loewen S; Riecke K
J Clin Pharmacol; 2020 Aug; 60(8):1030-1038. PubMed ID: 32227643
[TBL] [Abstract][Full Text] [Related]
3. Delafloxacin Pharmacokinetics in Subjects With Varying Degrees of Renal Function.
Hoover RK; Alcorn H; Lawrence L; Paulson SK; Quintas M; Cammarata SK
J Clin Pharmacol; 2018 Apr; 58(4):514-521. PubMed ID: 29251785
[TBL] [Abstract][Full Text] [Related]
4. Effect of renal impairment on the pharmacokinetics of prucalopride: a single- dose open-label Phase I study.
Smith WB; Mannaert E; Verhaeghe T; Kerstens R; Vandeplassche L; Van de Velde V
Drug Des Devel Ther; 2012; 6():407-15. PubMed ID: 23269861
[TBL] [Abstract][Full Text] [Related]
5. Conversion from cilostazol to OPC-13015 linked to mitigation of cognitive impairment.
Saito S; Shinmyozu K; Kawakami D; Yamauchi M; Ikeda S; Hattori Y; Yamamoto R; Hayakawa N; Ihara M
Alzheimers Dement (N Y); 2021; 7(1):e12182. PubMed ID: 34095441
[TBL] [Abstract][Full Text] [Related]
6. Cilostazol: a Review of Basic Mechanisms and Clinical Uses.
Kherallah RY; Khawaja M; Olson M; Angiolillo D; Birnbaum Y
Cardiovasc Drugs Ther; 2022 Aug; 36(4):777-792. PubMed ID: 33860901
[TBL] [Abstract][Full Text] [Related]
7. Role of Cilostazol Therapy in Hemodialysis Patients with Asymptomatic Peripheral Arterial Disease: A Retrospective Cohort Study.
Lim PS; Jeng Y; Wu MY; Pai MA; Wu TK; Chen CH
Biomed Res Int; 2016; 2016():8236903. PubMed ID: 27747241
[No Abstract] [Full Text] [Related]
8. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients.
Monserrat L; Elliott PM; Gimeno JR; Sharma S; Penas-Lado M; McKenna WJ
J Am Coll Cardiol; 2003 Sep; 42(5):873-9. PubMed ID: 12957435
[TBL] [Abstract][Full Text] [Related]
9. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions.
Wysowski DK; Corken A; Gallo-Torres H; Talarico L; Rodriguez EM
Am J Gastroenterol; 2001 Jun; 96(6):1698-703. PubMed ID: 11419817
[TBL] [Abstract][Full Text] [Related]
10. Oral antiplatelet drugs in patients with chronic kidney disease (CKD): a review.
Ibrahim H; Rao SV
J Thromb Thrombolysis; 2017 May; 43(4):519-527. PubMed ID: 28229274
[TBL] [Abstract][Full Text] [Related]
11. Measuring treatment effects of cilostazol on clinical trial endpoints in patients with intermittent claudication.
Smith JA
Clin Cardiol; 2002 Mar; 25(3):91-4. PubMed ID: 11892686
[TBL] [Abstract][Full Text] [Related]
12. Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease.
Bramer SL; Forbes WP; Mallikaarjun S
Clin Pharmacokinet; 1999; 37 Suppl 2():1-11. PubMed ID: 10702882
[TBL] [Abstract][Full Text] [Related]
13. Effect of multiple cilostazol doses on single dose lovastatin pharmacokinetics in healthy volunteers.
Bramer SL; Brisson J; Corey AE; Mallikaarjun S
Clin Pharmacokinet; 1999; 37 Suppl 2():69-77. PubMed ID: 10702889
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacokinetics of mycophenolate mofetil.
Bullingham RE; Nicholls AJ; Kamm BR
Clin Pharmacokinet; 1998 Jun; 34(6):429-55. PubMed ID: 9646007
[TBL] [Abstract][Full Text] [Related]
15. Antibiotic dosing in renal failure.
Maderazo EG
Med Clin North Am; 1995 Jul; 79(4):919-33. PubMed ID: 7791430
[TBL] [Abstract][Full Text] [Related]
16. Effect of renal impairment on the pharmacokinetics of cilostazol and its metabolites.
Mallikaarjun S; Forbes WP; Bramer SL
Clin Pharmacokinet; 1999; 37 Suppl 2():33-40. PubMed ID: 10702885
[TBL] [Abstract][Full Text] [Related]
17. Effect of hepatic impairment on the pharmacokinetics of a single dose of cilostazol.
Bramer SL; Forbes WP
Clin Pharmacokinet; 1999; 37 Suppl 2():25-32. PubMed ID: 10702884
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
